Dr Reddys closes sale of US rights for neurology products Tosymra, Zembrace Symtouch

Under the agreement, Dr Reddy's sold its US and select territory rights for Zembrace Symtouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg, which were commercialised through its wholly-owned subsidiary, Promius Pharma, LLC, it added.

New Delhi: Drug major Dr Reddy's Laboratories on Saturday said it has completed a sale of its US and select territory rights for two neurology products, Zembrace Symtouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg to Upsher-Smith Laboratories.

The company has closed the transaction with Upsher-Smith Laboratories LLC, "pursuant to the satisfactory completion of all customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended," Dr Reddy's Laboratories said in a filing to BSE.

Also Read: Dr Reddys unveils generic version of Allegra D in US to treat common cold, flu

Under the agreement, Dr Reddy's sold its US and select territory rights for Zembrace Symtouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg, which were commercialised through its wholly-owned subsidiary, Promius Pharma, LLC, it added.

Earlier in June this year, Dr Reddy's had said in a regulatory filing that it had entered into a definitive asset purchase agreement with Upsher-Smith Laboratories LLC to sell its US and select territory rights for the two products to the latter.

Under the agreement, Dr Reddy's was to receive USD 70 million as upfront consideration, USD 40.5 million in near term milestones and additional financial considerations including, existing contractual obligation and inventory, it had said.

Subsequently, Dr Reddy's was also to receive sales-based royalties on a quarterly basis, it had said.

Also Read: Dr Reddys launches OTC brand equivalent of Mucinex D ER tablets to treat phlegm